Secondary hormonal therapies in the treatment of prostate cancer

Urology

Volumn 60, Issue 3 SUPPL. 1, 2002, Pages 87-92

  Oh, William K ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANTIANDROGEN; BICALUTAMIDE; CORTICOSTEROID; DIETHYLSTILBESTROL; ESTROGEN; KETOCONAZOLE; PROSTATE SPECIFIC ANTIGEN;

ADRENAL INSUFFICIENCY; ANXIETY; ARTICLE; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; DISEASE COURSE; ESTROGEN THERAPY; HORMONAL THERAPY; HUMAN; LIVER TOXICITY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIODIAGNOSIS; STEROIDOGENESIS; SYMPTOM; THROMBOSIS; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 0036756361     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01581-9     Document Type: Article

References (36)

1. R.T. Greenlee M.B. Hill-Harmon T. Murray Cancer statistics, 2001 CA Cancer J Clin 51 2001 15 36
2. W.K. Oh P.W. Kantoff Management of hormone refractory prostate cancer current standards and future prospects J Urol 160 1998 1220 1229
3. P.W. Kantoff S. Halabi M. Conaway Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer results of the cancer and leukemia group B 9182 study J Clin Oncol 17 1999 2506 2513
4. I. Tannock M. Gospodarowicz W. Meakin Treatment of metastatic prostatic cancer with low-dose prednisone evaluation of pain and quality of life as pragmatic indices of response J Clin Oncol 7 1989 590 597
5. W.K. Kelly H.I. Scher Prostate specific antigen decline after antiandrogen withdrawal the flutamide withdrawal syndrome J Urol 149 1993 607 609
6. E.J. Small N.J. Vogelzang Second-line hormonal therapy for advanced prostate cancer a shifting paradigm J Clin Oncol 15 1997 382 388
7. E.J. Small P.R. Carroll Prostate-specific antigen decline after Casodex withdrawal evidence for an antiandrogen withdrawal syndrome Urology 43 1994 408 410
8. N.A. Dawson D.G. McLeod Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer expansion of the antiandrogen withdrawal syndrome J Urol 153 1995 1946 1947
9. M.E. Taplin G.J. Bubley Y.J. Ko Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist Cancer Res 59 1999 2511 2515
10. M.A. Fenton T.D. Shuster A.M. Fertig Functional characterization of mutant androgen receptors from androgen-independent prostate cancer Clin Cancer Res 3 1997 1383 1388
11. E.J. Small S. Halabi J. Picus A prospective randomized trial of antiandrogen withdrawal alone or antiandrogen withdrawal in combination with high-dose ketoconazole in androgen independent prostate cancer patients results of CALGB 9583 [abstract] Proc Am Soc Clin Oncol 20 2001 695
12. M.E. Taplin S. Halabi B. Rajeshkumar Androgen receptor mutations in androgen independent prostate cancer (APICA) do not correlate with anti-androgen withdrawal re-sponse Cancer and Leukemia Group B (CALGB) 9663 [abstract] Proc Am Soc Clin Oncol 20 2001 1738
13. R. Joyce M.A. Fenton P. Rode High dose bicalutamide for androgen independent prostate cancer effect of prior hormonal therapy J Urol 159 1998 149 153
14. O. Kucuk E. Fisher C.M. Moinpour Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed a Southwest Oncology Group study (SWOG 9235) Urology 58 2001 53 58
15. H.I. Scher C. Liebertz W.K. Kelly Bicalutamide for advanced prostate cancer the natural versus treated history of disease J Clin Oncol 15 1997 2928 2938
16. N.A. Dawson M. Conaway S. Halabi A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma cancer and leukemia group B study 9181 Cancer 88 2000 825 834
17. I.F. Tannock D. Osoba M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764
18. K. Nishimura N. Nonomura Y. Yasunaga Low doses of oral dexamethasone for hormone-refractory prostate carcinoma Cancer 89 2000 2570 2576
19. D.M. Reese E.J. Small Secondary hormonal manipulations in hormone refractory prostate cancer Urol Clin North Am 26 1999 311 321
20. N.A. Dawson Treatment of progressive metastatic prostate cancer Oncology (Huntingt) 7 1993 17 24 27–29
21. T. Eichenberger J. Trachtenberg P. Toor Ketoconazole a possible direct cytotoxic effect on prostate carcinoma cells J Urol 141 1989 190 191
22. E.J. Small A.D. Baron L. Fippin Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal J Urol 157 1997 1204 1207
23. R. Millikan L. Baez T. Banerjee Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer Urol Oncol 6 2001 111 115
24. K.A. Harris E.J. Small M.W. Frohlich Prospective trial of low dose ketoconazole (LDK) therapy in patients (Pts) with androgen-independent prostate cancer (AIPC) [abstract] Proc Am Soc Clin Oncol 20 2001 2419
25. E. Rosenbaum M. Wygoda M. Gips Diethylstilbestrol is an active agent in prostatic cancer patients after failure to complete androgen blockade [abstract] Proc Am Soc Clin Oncol 19 2000 1372
26. D.C. Smith B.G. Redman L.E. Flaherty A phase II trial of oral diethylstilbestrol as a second-line hormonal agent in advanced prostate cancer Urology 52 1998 257 260
27. M. Orlando M. Chacon G. Salum Low-dose continuous oral fosfestrol is highly active in “hormone-refractory” prostate cancer Ann Oncol 11 2000 177 181
28. M. Shahidi A.R. Norman J. Gadd Prospective review of diethylstilbestrol in advanced prostate cancer no longer responding to androgen suppression [abstract] Proc Am Soc Clin Oncol 20 2001 2455
29. C.N. Robertson K.M. Roberson G.M. Padilla Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells J Natl Cancer Inst 88 1996 908 917
30. T. Ades T. Gansler M. Miller PC-SPES current evidence and remaining questions CA Cancer J Clin 51 2001 199 204
31. T. Kubota J. Hisatake Y. Hisatake PC-SPES a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo Prostate 42 2000 163 171
32. A. de la Taille R. Buttyan O. Hayek Herbal therapy PC-SPES in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer J Urol 164 2000 1229 1234
33. R.S. DiPaola H. Zhang G.H. Lambert Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer N Engl J Med 339 1998 785 791
34. W.K. Oh D.J. George K. Hackmann Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer Urology 57 2001 122 126
35. B.L. Pfeifer J.F. Pirani S.R. Hamann PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer BJU Int 85 2000 481 485
36. E.J. Small M.W. Frohlich R. Bok Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer J Clin Oncol 18 2000 3595 3603